Testing PI3K Inhibitor BKM120 in Recurrent Glioblastoma
Glioblastoma multiforme (GBM), or grade 4 glioma, is an aggressive brain tumor that is resistant to chemotherapy and radiation, and is almost always fatal
DF/HCC Researchers Reinvent Anti-tumor IL-2 Therapy for GVHD
Graft-versus-host disease (GVHD) often occurs after an allogeneic hematopoietic stem cell transplant (HSCT) from a healthy donor is given to treat hematological cancers
The DNA Resource Core provides access to specialized resources such as rapid and user friendly high-throughput DNA sequencing, a cDNA/RNAi clone repository, and distribution services and informatics support
Under the direction of Annick Van den Abbeele, MD (DFCI) and Gordon Harris, PhD (MGH), the Tumor Imaging Metrics Core (TIMC) provides objective assessment of imaging response to treatments being evaluated through approved cancer clinical trials across the five DF/HCC hospitals (BIDMC, BWH, CHB, DFCI, MGH) using independent tumor measurements of radiological scans (CT, MR and PET). With convenient locations at BWH, DFCI and MGH, the TIMC produces high-quality data with fast turnaround time
